Phase II Clinical Trial of the Combination of RAD001 and Erlotinib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck.

Trial Profile

Phase II Clinical Trial of the Combination of RAD001 and Erlotinib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck.

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Feb 2016

At a glance

  • Drugs Everolimus (Primary) ; Erlotinib
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Nov 2014 Status changed from active, no longer recruiting to discontinued, according to M.D. Anderson Cancer Center record.
    • 20 Nov 2014 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
    • 01 Jul 2014 Planned primary completion date changed from 1 Jan 2015 to 1 Jan 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top